Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow 60 DEGREES PHARMACEUTICALS, INC.

Get SEC filing alerts via email and in your feed for 60 DEGREES PHARMACEUTICALS, INC.

SXTP SXTPW

60 DEGREES PHARMACEUTICALS, INC.

About 60 DEGREES PHARMACEUTICALS, INC.

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing innovative therapies for infectious diseases. Its flagship product, Arakoda, is a malaria preventative treatment, with ongoing research into its applications for babesiosis and other diseases. Targeting healthcare providers and patients, the company aims to expand its market presence through strategic clinical trials and partnerships, addressing significant unmet medical needs in infectious disease management.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from 60 DEGREES PHARMACEUTICALS, INC.

1
1
60 DEGREES PHARMACEUTICALS, INC. 60 Degrees Pharmaceuticals Reports Q1 2026 Financial Results with Increased Net Loss

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
60 DEGREES PHARMACEUTICALS, INC. 60 Degrees Pharmaceuticals Reports 65.5% Revenue Increase to $1.01 Million for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
60 DEGREES PHARMACEUTICALS, INC. 60 Degrees Pharmaceuticals Reports 223% Revenue Increase but Continues to Face Operational Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
60 DEGREES PHARMACEUTICALS, INC. 60 Degrees Pharmaceuticals Reports Q2 2025 Financial Results with Significant Revenue Growth

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
60 DEGREES PHARMACEUTICALS, INC. 60 Degrees Pharmaceuticals Reports Revenue Growth but Net Loss in Latest 10-Q Filing

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
60 DEGREES PHARMACEUTICALS, INC. 60 Degrees Pharmaceuticals Reports Revenue Growth to $607,574 Despite Increased Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
60 DEGREES PHARMACEUTICALS, INC. 60 Degrees Pharmaceuticals Reports Revenue Growth, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments